Table of Contents
Affinia Therapeutics said, on March 4, 2026, that the FDA has granted Fast Track designation for AFTX-201, its investigational AAV gene therapy for BAG3-associated dilated cardiomyopathy. The company also cited the FDA’s recent approval of its IND application for AFTX-201 and noted that the European Medicines Agency has designated AFTX-201 an Orphan Drug.
Fast Track can increase the cadence of FDA interactions during development and allow rolling review of a marketing application. In Affinia’s case, the designation is tied to UPBEAT, a multicenter, single-arm, open-label Phase 1/2 trial in adults with genetically confirmed BAG3-associated DCM. Affinia describes a dose-exploration phase followed by dose expansion, with safety and tolerability assessed through 52 weeks after a single intravenous administration.
Affinia’s approach relies on an engineered cardiac-tropic capsid intended to achieve efficient transduction at doses described as 5- to 10-fold lower than gene therapies using conventional capsids such as AAV9 or AAVrh74. Preclinical studies in an animal disease model are described as increasing BAG3 protein levels in the heart and completely restoring cardiac function.
In a November 2025 interview with Onyx, CEO Rick Modi said Affinia’s capsid (ATC-0187) was designed to enable lower dosing versus conventional AAV approaches, and he cited manufacturing and product-quality metrics including about ten times higher yield and a full-capsid percentage north of 90%. Modi also said Forge Biologics ran a 50-liter GMP batch that was sufficient to supply more than 100 patients for the first-in-human UPBEAT trial.
Comments